To evaluate the efficacy and safety of the drug for prevention of symptomatic COVID-19 infection in household contacts of an individual with COVID-19.
Criteria:Have at least 1 COVID-19 symptom within 24 hours before signing the ICF.
Have a positive COVID-19 test
Must have a potential study participant who can participate in the study within 72 hours after onset of COVID-19 symptoms in an index patient.